Safety and efficacy 31 week data of anavex 2-73 in a phase 2a study in mildmoderate Alzheimer's disease patients

Authors
Category Primary study
JournalAlzheimer's and Dementia
Year 2016
This article has no abstract
Epistemonikos ID: 4295a2c3275fc7e568afde7c64109417fdebbe41
First added on: Feb 08, 2025